Completed PHASE3 INTERVENTIONAL NCT00007735

Antibiotic Treatment of Gulf War Veterans' Illnesses

CSP #475 - Persian Gulf - Antibiotic Treatment Trial of Gulf War Veterans' Illnesses

Sponsor: Pfizer

Conditions Mycoplasma Infections Persian Gulf Syndrome

Interventions Doxycycline (200mg/day) or Placebo

Updated 8 times since 2017 Last updated: Oct 26, 2023 Started: Jan 31, 1999 Completion: Oct 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Mycoplasma Infections and Persian Gulf Syndrome, this trial is completed. The trial is conducted by Pfizer and has accumulated 8 data snapshots since 1999. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Nov 2023 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Nov 2023 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Aug 2018 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Aug 2018 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer
US Department of Veterans Affairs
United States Department of Defense

Data source: VA Office of Research and Development

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Albuquerque, United States , Augusta, United States , Birmingham, United States , Boston, United States , Brooklyn, United States , Charleston, United States , Durham, United States , East Orange, United States , Fargo, United States and 17 more locations